Standard-dose lansoprazole is more effective than high-dose ranitidine in achieving endoscopic healing and symptom relief in patients with moderately severe reflux oesophagitis

doi:10.1046/j.1365-2036.1999.00656.x

If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.

It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.

Wiley InterScience

Alimentary Pharmacology & Therapeutics

Volume 13 Issue 12, Pages 1611 - 1620

Published Online: 24 Dec 2001

< Previous Abstract | Next Abstract >

Save Article to My Profile Download Citation Request Permissions

Abstract | References | Full Text: HTML, PDF (Size: 218K) | Related Articles | Citation Tracking

Standard-dose lansoprazole is more effective than high-dose ranitidine in achieving endoscopic healing and symptom relief in patients with moderately severe reflux oesophagitis

Jansen & Van OeneON BEHALF OF THE DUTCH LANSOPRAZOLE STUDY GROUP

¹ Department of Gastroenterology, Academic Hospital Nijmegen St. Radboud, Nijmegen, the Netherlands, ² Department of Clinical Research, Janssen-Cilag BV, Tilburg, the Netherlands

Correspondence to: Jansen Dr

ABSTRACT

Background:

In the treatment of reflux oesophagitis, H₂-receptor antagonists are still widely used in spite of the apparent higher efficacy of proton pump inhibitors. In an attempt to compensate for the lower efficacy, H₂-receptor antagonists are now increasingly being used at a higher dose.

Objective:

To assess whether or not standard-dose lansoprazole (30 mg o.d.) is more effective than high-dose ranitidine (300 mg b.d.) in moderately severe reflux oesophagitis (grades II–III).

Methods:

Lansoprazole or ranitidine was given to 133 patients for 4–8 weeks in a double-blind, randomized, parallel group, multicentre trial.

Results:

The percentage of patients with endoscopically-verified healing was significantly higher on lansoprazole than on ranitidine both after 4 weeks (79% vs. 42%) and 8 weeks (91% vs. 66%), though smoking had a negative impact on oesophagitis healing with lansoprazole. Heartburn, retrosternal pain and belching improved significantly better with lansoprazole than with ranitidine, as did the patient-rated overall symptom severity. Relief of heartburn appeared somewhat faster with ranitidine, but was more pronounced with lansoprazole. The number of patients with adverse events was similar in both treatment groups.